tag:blogger.com,1999:blog-2741672436160438708.post2353544152950039889..comments2024-03-26T12:50:32.070-07:00Comments on Learning from and about cancer (chronic lymphocytic leukemia or CLL) by Dr. Brian Koffman: It's different in New YorkBrian Koffmanhttp://www.blogger.com/profile/13250684684103918493noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-2741672436160438708.post-47719401326206775182009-02-02T20:04:00.000-08:002009-02-02T20:04:00.000-08:00You write:"Their patients are young enough and ric...You write:<BR/>"Their patients are young enough and rich enough to travel to see them. Their patients cherry pick them."<BR/><BR/>I'd write, "Their patients cherry-picked themselves."<BR/><BR/>BTW, Revlimid has a poor response rate, less than 50%. Perhaps it will be better used as a 'maintenance' drug, though it's really too early to safely conclude that.Barry B.https://www.blogger.com/profile/16562498733714000836noreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-20446147124510055522009-01-31T12:05:00.000-08:002009-01-31T12:05:00.000-08:00What was odd about the MDA studhat their results w...What was odd about the MDA studhat their results were worse than the results Mayo presented at the same conference. As was explained to me by a PCR researcher, both the dose and patient set accounted for the terrible results. Thanks for the report.TomDhttps://www.blogger.com/profile/10903888177071549904noreply@blogger.com